Cyclerion Therapeutics (CYCN) Asset Utilization Ratio (2020 - 2025)
Cyclerion Therapeutics (CYCN) posted quarterly Asset Utilization Ratio of 0.29 for Q3 2025, up 1310.51% year-over-year from 0.02 in Q3 2024, and up 27.55% quarter-over-quarter from 0.23 in Q2 2025.
Cyclerion Therapeutics (CYCN) Asset Utilization Ratio (2020 - 2025) Analysis & Trends
Cyclerion Therapeutics' Asset Utilization Ratio history runs 6 years deep, the most recent figure standing at 0.29 for Q3 2025.
- In Q3 2025, Asset Utilization Ratio rose 1310.51% year-over-year to 0.29; the TTM figure through Sep 2025 stood at 0.29 (up 1310.51% YoY), while the FY2024 annual figure was 0.17, changed N/A from the prior year.
- Asset Utilization Ratio for Q3 2025 stood at 0.29, up from 0.23 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.29 in Q3 2025, with the low at 0.01 in Q1 2021.
- The 5-year median for Asset Utilization Ratio is 0.05 (2021), against an average of 0.1.
- The sharpest annual moves came in 2023 and 2025: Asset Utilization Ratio plunged 76.12% in 2023, then jumped 1310.51% in 2025.
- Cyclerion Therapeutics' Asset Utilization Ratio stood at 0.06 in 2021, then retreated by 24.01% to 0.05 in 2022, then slumped by 56.06% to 0.02 in 2023, then jumped by 944.98% to 0.22 in 2024, then surged by 33.28% to 0.29 in 2025.
- Business Quant data shows CYCN's Asset Utilization Ratio at 0.29 in Q3 2025, 0.23 in Q2 2025, and 0.21 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.13 |
| 10 | Cyclerion Therapeutics | 12.71 Mn | 9.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 0.29 |
| Jun 30, 2025 | 0.23 |
| Mar 31, 2025 | 0.21 |
| Dec 31, 2024 | 0.22 |
| Sep 30, 2024 | 0.02 |
| Mar 31, 2023 | 0.02 |
| Dec 31, 2022 | 0.05 |
| Sep 30, 2022 | 0.05 |
| Jun 30, 2022 | 0.05 |
| Mar 31, 2022 | 0.09 |
| Dec 31, 2021 | 0.06 |
| Sep 30, 2021 | 0.05 |
| Jun 30, 2021 | 0.04 |
| Mar 31, 2021 | 0.01 |
| Dec 31, 2020 | 0.02 |
| Sep 30, 2020 | 0.03 |
| Jun 30, 2020 | 0.03 |
| Mar 31, 2020 | 0.03 |